Phase I/II Trial of the Combination of Midostaurin (PKC412) and 5-Azacytidine for Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

We investigated the combination of midostaurin and azacitidine (AZA) in patients with AML and high risk MDS. Patients received AZA 75 mg/m(2) on days 1–7 and midostaurin 25 mg bid (in cohort 1 of phase I) or 50 mg bid (in cohort 2 of Phase I and in Phase II) orally on day 8–21 during the first cycle...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Hematol
Autors principals: Strati, Paolo, Kantarjian, Hagop, Ravandi, Farhad, Nazha, Aziz, Borthakur, Gautam, Daver, Naval, Kadia, Tapan, Estrov, Zeev, Garcia-Manero, Guillermo, Konopleva, Marina, Rajkhowa, Trivikram, Durand, Menda, Andreeff, Michael, Levis, Mark, Cortes, Jorge
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4376596/
https://ncbi.nlm.nih.gov/pubmed/25530214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23924
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars